The shared goals of the Global Malaria Programme (GMP) and the Global Programme to Eliminate Lymphatic Filariasis (GPELF) will be presented, highlighting the opportunities and challenges for the integration of VBD control strategies at a programmatic level. The GPELF strategy to interrupt transmission including mass drug administration (MDA) using different regimen combinations of albendazole, ivermectin and diethylcarbamazine, supplemented with vector control will be summarised with case-studies highlighting how i) large-scale malaria vector control programmes have significantly reduced LF transmission in several countries, and consequently reduced the need for MDA and helped to accelerate elimination; ii) the complexity of Loa loa co-endemicity in Central Africa and the risk of severe adverse events associated with ivermectin MDA has been a major barrier for LF programmes, and consequently resulted in the need for alternative strategies including insecticide treated/long-lasting bed nets (ITNs/LLINs); and iii) as national LF programmes successfully interrupt transmission and scale-down MDA, closer links with malaria control programmes will be essential to monitor the continuing impact of vector control and help develop integrated surveillance platforms.